NEW YORK, July 5 /PRNewswire/ -- PeriCor Therapeutics, Inc. announced the election of Robert L. Engler, M.D. to the Company’s Board of Directors. Since 2005, Dr. Engler has been a member of PeriCor’s Scientific Advisory Board. Currently, he is Professor of Medicine, Emeritus at the University of California, San Diego (UCSD) School of Medicine and in addition, serves as Chief Medical Advisor at Cardium Therapeutics.
“We are delighted that Dr. Engler has agreed to join the PeriCor Board of Directors,” stated Richard R. Stover, President and CEO of PeriCor Therapeutics. “Dr. Engler brings over 35 years of experience in cardiovascular medicine and research to the Board. Over the course of his career, he has been a pioneer in the research of ischemia/reperfusion injury, ischemic preconditioning, and adenosine cardioprotection as well as in pharmaceutical development in corporate settings. We expect to rely heavily on his blended experience in research and pharmaceutical development as PeriCor Therapeutics takes its next steps in realizing the opportunities that its portfolio of products presents.”
Dr. Engler was Professor of Medicine at UCSD, Associate Chief of Staff for Research and Development at the Veterans’ Affairs Medical Center, and a faculty member of the Institute for Biomedical Engineering at UCSD. He served as director of Coronary Care at the VA Hospital and was a clinical cardiologist until 2001 when he retired from UCSD and the VA Hospital to continue his work in the development of innovative agents for cardiovascular therapy. From 1985 to 1997, Dr. Engler was co-founder and Scientific Advisor to Gensia. He was also co-founder of Collateral Therapeutics (subsequently sold to Schering AG) and served as a Director from 1995 to 2000 and as Vice President, Medical Director from 1995 through 1998. Dr. Engler is a member of the Board of Directors of Halozyme Therapeutics, a publicly-traded biotechnology company, and of Coda Genomics. He received a B.A. in Physics from the University of North Carolina and his medical degree from Georgetown University.
About PeriCor Therapeutics
PeriCor Therapeutics, Inc. is a privately-held specialty biopharmaceutical company focused on the development and commercialization of a new class of medicines, adenosine regulating agents, to prevent the perioperative complications of surgery and improve the treatment and outcomes of acute cardiovascular care.
PeriCor Therapeutics, Inc.
CONTACT: Richard R. Stover of PeriCor Therapeutics, Inc., +1-212-601-2725;or Robert Cavosi of Broadgate Consultants for PeriCor Therapeutics, Inc.,+1-212-493-6981
